Oligodendroglioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
- $ 2000
- April 2024
- 106 pages
Pemigatinib (INCB-54828) is under development for the treatment of newly diagnosed acute myeloid leukemia, gastric cancer, adenocarcinoma of the gastroesophageal junction, non-muscle invasive bladder cancer, metastatic or unresectable urothelial carcinoma, advanced malignancies such as solid tumors including squamous non-small cell lung cancer, gastric cancer, gastroesophageal junction carcinoma, bile duct cancer, urothelial carcinoma, breast/endometrial cancer, myeloproliferative neoplasms (myeloid/lymphoid neoplasms), multiple myeloma, bladder cancer, colorectal cancer, recurrent glioblastoma,astrocytoma, oligodendroglioma, pilocytic astrocytoma, esophageal carcinoma and metastatic or surgically unresectable adeno squamous carcinoma of the pancreas.